Jakobs Tobias F, Hoffmann Ralf Th, Trumm Christoph, Reiser Maximilian F, Helmberger Thomas K
Department of Radiology, University of Munich, Germany.
Anticancer Res. 2006 Jan-Feb;26(1B):671-80.
The aim of this retrospective study was to evaluate the efficacy and medium-term survival, after percutaneous radiofrequency ablation (RFA), in patients suffering from hepatic metastases of colorectal cancer.
Between 2000 and 2004, 68 patients (42 men, 26 women; mean age 63 years, range: 38-87 years), with non-resectable liver metastases from colorectal cancer, were treated by RFA subsequently or parallel to chemotherapy. The procedures were mainly performed under conscious sedation and local anesthesia using computed tomography fluoroscopy guidance. The number of lesions, the primary success rate, complications, follow-up time and disease-free survival, as well as the local recurrence rate, were evaluated.
One-hundred and eighty-three metastases with a mean diameter of 22.8 mm (5-50 mm) in 68 patients (2.7 +/- 1.1 lesions / patient) were successfully treated using RFA. No major complications and only 4 minor complications were noted. Over an average follow-up period of 21.4 +/- 10.6 months (range, 8 to 38 months), Kaplan-Meier analysis demonstrated a probability of 82% of remaining locally disease-free and a probability of 68% of surviving the first 38 months after treatment.
For patients with non-resectable hepatic metastases of colorectal cancer, RFA is a safe option in a multimodal treatment concept and may lead to an improvement in survival.
本回顾性研究的目的是评估经皮射频消融（RFA）治疗结直肠癌肝转移患者的疗效和中期生存率。
2000年至2004年间，68例（42例男性，26例女性；平均年龄63岁，范围：38 - 87岁）患有不可切除的结直肠癌肝转移患者，接受了RFA治疗，随后或与化疗同时进行。手术主要在清醒镇静和局部麻醉下，使用计算机断层扫描荧光透视引导进行。评估了病灶数量、初次成功率、并发症、随访时间和无病生存率，以及局部复发率。
68例患者（平均每位患者2.7±1.1个病灶）中的183个转移灶（平均直径22.8 mm，范围5 - 50 mm）成功接受了RFA治疗。未发现重大并发症，仅记录到4例轻微并发症。在平均21.4±10.6个月（范围8至38个月）的随访期内，Kaplan - Meier分析显示局部无病生存率为82%，治疗后前38个月的生存率为68%。
对于不可切除的结直肠癌肝转移患者，RFA在多模式治疗方案中是一种安全的选择，可能会提高生存率。
